P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847576.88118.d6 |
| _version_ | 1827336374018113536 |
|---|---|
| author | N. L. Bartlett C. A. Yasenchak K. K. Ashraf W. N. Harwin J. Orcutt P. Kuriakose P. L. Zinzani A. Mamidipalli K. Fenton C. Glenn G. Nowakowski |
| author_facet | N. L. Bartlett C. A. Yasenchak K. K. Ashraf W. N. Harwin J. Orcutt P. Kuriakose P. L. Zinzani A. Mamidipalli K. Fenton C. Glenn G. Nowakowski |
| author_sort | N. L. Bartlett |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:34Z |
| format | Article |
| id | doaj.art-0186ace057a94510ac5556939fac7551 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:34Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-0186ace057a94510ac5556939fac75512024-03-02T06:40:32ZengWileyHemaSphere2572-92412022-06-0161064106510.1097/01.HS9.0000847576.88118.d6202206003-01064P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDYN. L. Bartlett0C. A. Yasenchak1K. K. Ashraf2W. N. Harwin3J. Orcutt4P. Kuriakose5P. L. Zinzani6A. Mamidipalli7K. Fenton8C. Glenn9G. Nowakowski101 Washington University School of Medicine, St. Louis, MO2 Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR3 Hem-Onc Assocs, Birmingham, AL4 Florida Cancer Specialists and Research Institute, Fort Myers, FL5 Charleston Hematology Oncology Associates, Charleston, SC6 Henry Ford Health System, Detroit, MI, United States of America7 Institute of Hematology “L. e A. Seràgnoli”, University of Bologna9 Seagen Inc., Bothell, WA9 Seagen Inc., Bothell, WA9 Seagen Inc., Bothell, WA10 Division of Hematology, Mayo Clinic, Rochester, MN, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847576.88118.d6 |
| spellingShingle | N. L. Bartlett C. A. Yasenchak K. K. Ashraf W. N. Harwin J. Orcutt P. Kuriakose P. L. Zinzani A. Mamidipalli K. Fenton C. Glenn G. Nowakowski P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY HemaSphere |
| title | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_full | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_fullStr | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_full_unstemmed | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_short | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_sort | p1178 brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed refractory dlbcl safety and efficacy results from the safety run in period of the phase 3 echelon 3 study |
| url | http://journals.lww.com/10.1097/01.HS9.0000847576.88118.d6 |
| work_keys_str_mv | AT nlbartlett p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT cayasenchak p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT kkashraf p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT wnharwin p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT jorcutt p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT pkuriakose p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT plzinzani p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT amamidipalli p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT kfenton p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT cglenn p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT gnowakowski p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study |